Mastrangelo MJ - Search Results

1

Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens.

Berd D, Herlyn M, Koprowski H, Mastrangelo MJ. Berd D, et al. Among authors: mastrangelo mj. Cancer Res. 1989 Dec 1;49(23):6840-4. Cancer Res. 1989. PMID: 2582430

2

Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.

Berd D, Sato T, Mastrangelo MJ. Berd D, et al. Among authors: mastrangelo mj. Cancer Immunol Immunother. 2002 Aug;51(6):320-6. doi: 10.1007/s00262-002-0285-3. Epub 2002 Jun 6. Cancer Immunol Immunother. 2002. PMID: 12111120 Free PMC article. Clinical Trial.

3

Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.

Ohta M, Nagai H, Shimizu M, Rasio D, Berd D, Mastrangelo M, Singh AD, Shields JA, Shields CL, Croce CM, et al. Ohta M, et al. Cancer Res. 1994 Oct 15;54(20):5269-72. Cancer Res. 1994. PMID: 7923152

4

Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases.

Berd D, Murphy G, Maguire HC Jr, Mastrangelo MJ. Berd D, et al. Among authors: mastrangelo mj. Cancer Res. 1991 May 15;51(10):2731-4. Cancer Res. 1991. PMID: 2021952

5

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ. Berd D, et al. Among authors: mastrangelo mj. J Clin Oncol. 1990 Nov;8(11):1858-67. doi: 10.1200/JCO.1990.8.11.1858. J Clin Oncol. 1990. PMID: 2230873

6

Depletion of T-cells with the CD4+CD45R+ phenotype in lymphocytes that infiltrate subcutaneous metastases of human melanoma.

Cardi G, Mastrangelo MJ, Berd D. Cardi G, et al. Among authors: mastrangelo mj. Cancer Res. 1989 Dec 1;49(23):6562-5. Cancer Res. 1989. PMID: 2479465

7

Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.

Berd D, Mastrangelo MJ. Berd D, et al. Among authors: mastrangelo mj. Cancer Res. 1988 Mar 15;48(6):1671-5. Cancer Res. 1988. PMID: 2830969

8

The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma.

McClay EF, Mastrangelo MJ, Sprandio JD, Bellet RE, Berd D. McClay EF, et al. Among authors: mastrangelo mj. Cancer. 1989 Apr 1;63(7):1292-5. doi: 10.1002/1097-0142(19890401)63:7<1292::aid-cncr2820630711>3.0.co;2-i. Cancer. 1989. PMID: 2920358

9

Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.

Berd D, Mastrangelo MJ. Berd D, et al. Among authors: mastrangelo mj. Cancer Invest. 1988;6(3):337-49. doi: 10.3109/07357908809080657. Cancer Invest. 1988. PMID: 3167614

10

Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells.

Herlyn M, Clark WH Jr, Mastrangelo MJ, Guerry DP 4th, Elder DE, LaRossa D, Hamilton R, Bondi E, Tuthill R, Steplewski Z, Koprowski H. Herlyn M, et al. Among authors: mastrangelo mj. Cancer Res. 1980 Oct;40(10):3602-9. Cancer Res. 1980. PMID: 6159966

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

195 results

Search Page

Filters